Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 9Active not recruiting 4Withdrawn 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC) 1

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 8toripalimab 7darolutamide 7Drug Therapy 7Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Axitinib 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Cyclophosphamide 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lutetium-177 × Genitourinary × Clear all
NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Cellbion Co., Ltd.

Phase 1 Not yet recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡